JPH05229956A - Antioxidant - Google Patents

Antioxidant

Info

Publication number
JPH05229956A
JPH05229956A JP4072212A JP7221292A JPH05229956A JP H05229956 A JPH05229956 A JP H05229956A JP 4072212 A JP4072212 A JP 4072212A JP 7221292 A JP7221292 A JP 7221292A JP H05229956 A JPH05229956 A JP H05229956A
Authority
JP
Japan
Prior art keywords
antioxidant
extract
carthamus tinctorius
ethanol
carthamus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP4072212A
Other languages
Japanese (ja)
Other versions
JP3206952B2 (en
Inventor
Yoshio Koizumi
義夫 小泉
Kenji Shimomura
健次 下村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mikimoto Pharmaceutical Co Ltd
Original Assignee
Mikimoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mikimoto Pharmaceutical Co Ltd filed Critical Mikimoto Pharmaceutical Co Ltd
Priority to JP07221292A priority Critical patent/JP3206952B2/en
Publication of JPH05229956A publication Critical patent/JPH05229956A/en
Application granted granted Critical
Publication of JP3206952B2 publication Critical patent/JP3206952B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

PURPOSE:To obtain an antioxidant containing an extract of Carthamus Tinctorius L. with an solvent, excellent in safety and further having action capable of inhibiting activity of hyaluronidase. CONSTITUTION:The objective antioxidant contains an extract obtained by extracting Carthamus Tinctorius L. which is a plant belonging to Dicotyledoneae, Sympetalae, Campanulales, Compositae, Carthamus with a hydrophilic organic solvent (e.g. ethanol) as an active ingredient. The extract of Carthamus Tinctorius L. has strong antioxidant action and is a natural product and has been for long years used as an emmenagogue and an blood cleaning agent in treatment for women's disease, oversensitive condition to cold, climacteric disturbance, etc., and has high safety to human. The agent retains lubricating property and softness of skin and has effect capable of suppressing decomposition of hyaluronic acid preventing outer force and bacterial cell.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は酸化防止剤に関するもの
で、更にヒアルロニダーゼの活性を阻害することに関し
ても有効な酸化防止剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an antioxidant, and further relates to an antioxidant effective in inhibiting the activity of hyaluronidase.

【0002】[0002]

【従来の技術】べは花は双子葉植物網、合弁花亜網、き
きょう目、きく科ベニバナ属の学名をカルタムス チン
クトリウス エル(Carthamus Tinctorius L. )ベニバ
ナ又はクレノアイとも呼ばれる植物の花である。紅花は
通経、浄血薬として婦人病、冷え症、更年期障害等の治
療に用いられる。また色素として古くより口紅等に用い
られている。
2. Description of the Related Art Vegetation is a flower of dicotyledonous plant, joint-venture sub-net, Cryptera, and the scientific name of the family Asteraceae is Carthamus Tinctorius L. safflower or Klenoai. Safflower is used as a blood purifying drug for the treatment of women's diseases, chills, and menopause. It has also been used as a pigment for lipsticks since ancient times.

【0003】現在、主として利用されている酸化防止剤
はブチルヒドロキシアンソニール(BHA)、ブチルヒ
ドロキシトルエン(BHT)、ビタミンEやその誘導体
がある。BHAやBHTは合成品であり、現在一般的な
常識として、合成品の使用には、長期的な安全性が保証
されていないことから厳しい非難があり、実際の法規制
でも使用が甚だしく規制されつつある。またビタミンE
やその誘導体は、合成品もあるが、米糠等の天然物に含
まれ安全性は十分であるが、酸化防止作用が比較的弱
く、天然物で強い酸化作用のある物質が望まれている。
At present, the antioxidants mainly used are butylhydroxyanthony (BHA), butylhydroxytoluene (BHT), vitamin E and its derivatives. BHA and BHT are synthetic products, and as a general common sense nowadays, the use of synthetic products is subject to severe criticism because long-term safety is not guaranteed. It's starting. Also vitamin E
Synthetic products and derivatives thereof are included in natural products such as rice bran and have sufficient safety, but substances having a relatively weak antioxidant action and having a strong oxidizing action are desired.

【0004】[0004]

【発明が解決しようとする課題】本発明の目的は強い酸
化防止作用があり、且つ天然物で永年人体に内用等で使
用され、人体への安全性が確認されており、更に酸化防
止作用以外の効果も発揮するような酸化防止剤を提供す
ることである。
The object of the present invention is to have a strong antioxidative effect, and it has been confirmed that it is a natural product and has been used internally for many years in the human body, and its safety to the human body has been confirmed. It is to provide an antioxidant that exerts effects other than the above.

【0005】[0005]

【課題を解決するための手段】本発明者らは、前記課題
を解決する物質を植物、動物、食品等の天然物質よりス
クリーニングして調べた結果、紅花の溶媒抽出物が強い
酸化防止作用を有することを見い出して、本発明を完成
した。
Means for Solving the Problems As a result of screening the substances for solving the above problems from natural substances such as plants, animals and foods, the present inventors have found that the solvent extract of safflower has a strong antioxidant action. The present invention was completed by finding out that they have.

【0006】すなわち本発明は紅花の溶媒抽出物を有効
成分とする酸化防止剤である。
That is, the present invention is an antioxidant containing a solvent extract of safflower as an active ingredient.

【0007】紅花は国内で自生しており、その入手は容
易であり、且つ医薬品原料として市販されている。この
紅花を親水性有機溶媒で抽出するが、この溶媒としては
一般的にはエタノールさらにはメタノール、ブタノー
ル、アセトンまたはこれらの混合物が使用できる。また
それの一部を水に置き換えることも可能である。また、
1,3ブチレングリコール、グリセリン等の多価アルコ
ールも用いることが出来る。ヒアルロニダーゼの活性阻
害や酸化防止の効果から見ると、50%前後のエタノー
ル水溶液による抽出が適当であった。
[0007] Safflower grows naturally in Japan, is easily available, and is marketed as a raw material for pharmaceuticals. The safflower is extracted with a hydrophilic organic solvent, and as the solvent, generally ethanol, methanol, butanol, acetone or a mixture thereof can be used. It is also possible to replace part of it with water. Also,
Polyhydric alcohols such as 1,3 butylene glycol and glycerin can also be used. Judging from the effects of hyaluronidase activity inhibition and antioxidant, extraction with an aqueous solution of about 50% ethanol was appropriate.

【0008】本発明の酸化防止剤はまた、他の酸化防止
剤との併用もまた可能であり、ビタミンEや、本出願人
による特願平2−138457号のコンキオリン加水分
解物や、特願平3−217484号公報のカシューナッ
ツよりの抽出物との併用もできる。酸化防止剤として配
合する対象としては特に限定はなく、化粧料などは塗布
後の酸化防止作用もあるので有効である、即ちこの酸化
防止作用は製剤中のみならず、皮膚に塗布した後も有効
であるので、皮脂の酸化防止効果もある。また化粧料の
剤形に特に限定はなく、クリーム、ローション、パック
等に配合することが可能である。
The antioxidant of the present invention can also be used in combination with other antioxidants, such as vitamin E, the conchiolin hydrolyzate of Japanese Patent Application No. 2-138457 by the present applicant, and the Japanese Patent Application. It can also be used in combination with the extract from cashew nuts of JP-A-3-217484. There is no particular limitation on the target compounded as an antioxidant, and cosmetics and the like are effective because they also have an antioxidant effect after application, that is, this antioxidant effect is effective not only in the preparation but also after application to the skin. Therefore, it also has an antioxidant effect on sebum. Further, the dosage form of the cosmetic is not particularly limited, and it can be blended in creams, lotions, packs and the like.

【0009】[0009]

【実施例】以下に実施例により、本発明を更に具体的に
説明するが、本発明は、この実施例によって何等限定さ
れるものではない。
The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.

【0010】実施例において、使用した本発明の酸化防
止剤の製造例を示す。 (製造例1)紅花10gにエタノール200mlを加えて
5日間放置した。これをNo5C濾紙でロ過して、これ
を凍結乾燥した。
In the examples, production examples of the antioxidant of the present invention used will be shown. (Production Example 1) 200 g of ethanol was added to 10 g of safflower and left for 5 days. This was filtered with No5C filter paper and freeze-dried.

【0011】(製造例2)紅花10gに50%エタノー
ル200mlを加えて5日間放置した。これをNo5C濾
紙でロ過し、これを凍結乾燥した。
(Production Example 2) 200 g of 50% ethanol was added to 10 g of safflower and left for 5 days. This was filtered with No5C filter paper and freeze-dried.

【0012】 (実施例1)ローション オリーブ油 0.5 製造例1の紅花のエタノール抽出物 0.5 ポリオキシエチレン(20E.O.)ソルビタンモノステアレート 2.0 ポリオキシエチレン(60E.O.)硬化ヒマシ油 2.0 エタノール 10.0 1.0%ヒアルロン酸ナトリウム水溶液 5.0 精製水 80.0(Example 1) Lotion Olive oil 0.5 Ethanol extract of safflower of Production Example 1 0.5 Polyoxyethylene (20 E.O.) sorbitan monostearate 2.0 Polyoxyethylene (60 E.O.) Hydrogenated castor oil 2.0 Ethanol 10.0 1.0% sodium hyaluronate aqueous solution 5.0 Purified water 80.0

【0013】 (実施例2)クリーム A スクワラン 20.0 オリーブ油 2.0 ミンク油 1.0 ホホバ油 5.0 ミツロウ 5.0 セトステアリルアルコール 2.0 グリセリンモノステアレート 1.0 ソルビタンモノステアレート 2.0 製造例2の紅花の50%エタノール抽出物 1.0 B 精製水 47.9 ポリオキシエチレン(20E.O.)ソルビタンモノステアレート 2.0 ポリオキシエチレン(60E.O.)硬化ヒマシ油 1.0 グリセリン 5.0 1.0%ヒアルロン酸ナトリウム水溶液 5.0 パラオキシ安息香酸メチル 0.1 AとBをそれぞれ計量し、70℃まで加温し、BにAを
撹拌しつつ徐々に加えたのち、ゆっくり撹拌しつつ30
℃まで冷却した。
Example 2 Cream A Squalane 20.0 Olive Oil 2.0 Mink Oil 1.0 Jojoba Oil 5.0 Beeswax 5.0 Cetostearyl Alcohol 2.0 Glycerin Monostearate 1.0 Sorbitan Monostearate 2 .0 50% ethanol extract of safflower of Production Example 1 1.0 B Purified water 47.9 Polyoxyethylene (20 E.O.) sorbitan monostearate 2.0 Polyoxyethylene (60 E.O.) hydrogenated castor oil 1.0 Glycerin 5.0 1.0% sodium hyaluronate aqueous solution 5.0 Methyl paraoxybenzoate 0.1 Weigh A and B respectively, heat to 70 ° C., and gradually add A to B with stirring After that, while stirring slowly, 30
Cooled to ° C.

【0014】(抗酸化試験)以下の試験液をネジキャッ
プ付50ml試験管に作成した。 検体 5mg 1%リノール酸エタノール溶液 10ml 0.1M,pH7.0リン酸緩衝液 10ml 精製水 5ml これを40℃の恒温槽に遮光して放置する。これを恒温
槽に入れる前、4日後、8日後、12日後、17日後に
以下の測定をした。試験液0.125ml、75%エタノ
ール12.125ml、30%チオシアン酸アンモニウム
0.125mlを加えて撹拌し3分間放置後、0.02N
塩化第一鉄3.5%HC1水溶液0.125mlを加えて
撹拌し3分間放置後波長500nmで吸光度を測定し
た。セル長10mm、対照セルはブランクとして試験液を
水に置き換えたもの。(同一検体を3回測定し、平均し
た) 測定結果を、対照例の水及び比較例1 ビタミンE、比
較例2 BHTの結果と共に表1に示す。
(Antioxidant test) The following test solutions were prepared in 50 ml test tubes with screw caps. Specimen 5 mg 1% ethanolic linoleic acid solution 10 ml 0.1 M, pH 7.0 phosphate buffer 10 ml purified water 5 ml This is left in a constant temperature bath at 40 ° C while being shielded from light. The following measurements were taken before 4 days, 8 days, 12 days, and 17 days before putting this in a constant temperature bath. 0.125 ml of test solution, 12.125 ml of 75% ethanol, and 0.125 ml of 30% ammonium thiocyanate were added, stirred and left for 3 minutes, then 0.02N
0.125 ml of 3.5% ferric chloride aqueous solution of HC1 was added, and the mixture was stirred and allowed to stand for 3 minutes, and then the absorbance was measured at a wavelength of 500 nm. The cell length was 10 mm, and the control cell was a blank in which the test solution was replaced with water. (The same sample was measured three times and averaged) The measurement results are shown in Table 1 together with the results of the water of the control example, Vitamin E of Comparative Example 1, and BHT of Comparative Example 2.

【0015】[0015]

【表1】 [Table 1]

【0016】(ヒアルロニダーゼ活性抑制試験)ヒアル
ロニダーゼは生体中に広く分布し、皮膚にも存在する。
その名の通りヒアルロン酸を分解する。ヒアルロン酸は
β‐D‐N‐アセチルグルコサミンとβ‐D‐グルクロ
ン酸が交互に結合した直鎖状の高分子多糖で、コンドロ
イチン硫酸などとともに哺乳動物の結合組織に広く存在
するグリコサミノグリカンの一種である。結合組織内の
ヒアルロン酸の機能として、細胞間隙に水を保持し、ま
た組織内にジェリー状のマトリックスを形成して細胞を
保持したり、皮膚の潤滑性と柔軟性を保ち、外力(機械
的傷害)および細菌感染を防止していると考えられてい
る。従って、このヒアルロニダーゼの活性を抑制するこ
とは、ヒアルロン酸の分解を抑え、この製剤の使用中の
ヒアルロン酸の安定性や皮膚に塗布した後の製剤のヒア
ルロン酸の安定、又皮膚に存在するヒアルロン酸自体の
安定にも寄与すると考えられる。
(Hyaluronidase activity inhibition test) Hyaluronidase is widely distributed in the living body and is also present in the skin.
As its name implies, it decomposes hyaluronic acid. Hyaluronic acid is a linear polymeric polysaccharide in which β-D-N-acetylglucosamine and β-D-glucuronic acid are alternately linked, and is a glycosaminoglycan that is widely present in connective tissues of mammals along with chondroitin sulfate. It is a kind. As a function of hyaluronic acid in connective tissue, it retains water in the intercellular spaces, forms a jelly-like matrix in the tissue to retain cells, keeps skin's lubricity and flexibility, and exerts external force (mechanical force). Injury) and bacterial infections. Therefore, suppressing the activity of this hyaluronidase suppresses the degradation of hyaluronic acid, the stability of hyaluronic acid during the use of this formulation, the stability of hyaluronic acid in the formulation after application to the skin, and the hyaluronic acid present in the skin. It is also considered to contribute to the stability of the acid itself.

【0017】(試験方法)0.4%ヒアルロン酸ナトリ
ウム0.1M(pH6.0)リン酸緩衝溶液を6gはか
りとり、37℃恒温水槽で5分間放置後、前記製造例
(凍結乾燥品)の0.1wt/v %水溶液(溶解しにくい
場合はエタノールを加えて溶解したのち精製水を加え
て、エバポレートし、エタノールを除去したのち、0.
1wt/v %になるように調整した)1.0mlを加え撹拌
し、0.01%ヒアルロニダーゼ(シグマ社製牛睾丸
製、タイプI−S)0.1M(pH6.0)リン酸緩衝
溶液を1ml加えて直ちに撹拌し、6mlを37℃の恒温水
槽に入れたオストワルド粘度計に入れた。これを1分
後、5分後、10分後、20分後、40分後に粘度を測
定した。1分後の粘度を100として、指数で表示す
る。対照として、上記試料液のかわりに純水を加え同様
に測定した。この試験では試料の終濃度は0.0125
%となる。この測定結果を表2に示す。
(Test Method) 6 g of 0.4% sodium hyaluronate 0.1M (pH 6.0) phosphate buffer solution was weighed and left in a 37 ° C. constant temperature water bath for 5 minutes. 0.1 wt / v% aqueous solution (if it is difficult to dissolve, add ethanol to dissolve it, then add purified water and evaporate to remove ethanol.
1.0 ml (adjusted to be 1 wt / v%) was added and stirred, and 0.01% hyaluronidase (manufactured by Sigma, beef testis, type I-S) 0.1M (pH 6.0) phosphate buffer solution was added. 1 ml was added and immediately stirred, and 6 ml was placed in an Ostwald viscometer placed in a constant temperature water bath at 37 ° C. The viscosity was measured after 1 minute, 5 minutes, 10 minutes, 20 minutes, and 40 minutes. Viscosity after 1 minute is set to 100 and displayed as an index. As a control, pure water was added instead of the sample solution and the same measurement was performed. The final concentration of the sample in this test is 0.0125
%. The results of this measurement are shown in Table 2.

【0018】[0018]

【表2】 この結果より、製造例2の50%エタノール水溶液で抽
出したものが特にヒアルロニダーゼ活性抑制効果が大き
いことがわかる。
[Table 2] From these results, it can be seen that the product extracted with the 50% ethanol aqueous solution of Production Example 2 has a particularly large effect of suppressing hyaluronidase activity.

【0019】(パネルテスト)女性8名に1月間実施例
と比較例を左右の顔面を用いて連用してもらった。実施
例と比較例ともにローション、クリームを併用した。比
較例は実施例より製造例を除いたものである。結果を表
3に示す。 1=比較例の方がよい 4=実施例の方
がややよい 2=比較例の方がややよい 5=実施例の方
がよい 3=差がない。
(Panel test) Eight women were asked to continuously use the embodiment and comparative example for one month using their right and left faces. Lotions and creams were used in combination in both Examples and Comparative Examples. The comparative example is obtained by removing the manufacturing example from the example. The results are shown in Table 3. 1 = Comparative example is better 4 = Example is better 2 = Comparative example is better 5 = Example is better 3 = No difference

【0020】[0020]

【表3】 [Table 3]

【0021】[0021]

【発明の効果】本発明の酸化防止剤は、強い酸化防止作
用があり、且つ天然物で、永年人体に内用等により適用
され、人体に対する安全性が確認されている。抽出溶剤
により若干差はあるが、酸化防止作用以外にヒアルロニ
ダーゼ活性抑制効果も認められる。化粧料等に配合し
て、皮脂の酸化防止、皮膚に存在するヒアルロン酸の安
定にも寄与し、優れた効果を発揮する。
EFFECT OF THE INVENTION The antioxidant of the present invention has a strong antioxidant action, is a natural product, and has been applied to the human body for many years for internal use, and its safety to the human body has been confirmed. Although there is a slight difference depending on the extraction solvent, a hyaluronidase activity suppressing effect is recognized in addition to the antioxidant effect. When added to cosmetics and the like, it contributes to the antioxidant of sebum and the stability of hyaluronic acid present in the skin, and exhibits excellent effects.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 // C12N 9/99 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display location // C12N 9/99

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 紅花の溶媒抽出物を有効成分とする酸化
防止剤。
1. An antioxidant comprising a safflower solvent extract as an active ingredient.
JP07221292A 1992-02-24 1992-02-24 Antioxidant Expired - Lifetime JP3206952B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP07221292A JP3206952B2 (en) 1992-02-24 1992-02-24 Antioxidant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP07221292A JP3206952B2 (en) 1992-02-24 1992-02-24 Antioxidant

Publications (2)

Publication Number Publication Date
JPH05229956A true JPH05229956A (en) 1993-09-07
JP3206952B2 JP3206952B2 (en) 2001-09-10

Family

ID=13482714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP07221292A Expired - Lifetime JP3206952B2 (en) 1992-02-24 1992-02-24 Antioxidant

Country Status (1)

Country Link
JP (1) JP3206952B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240510A (en) * 2000-03-01 2001-09-04 Kenji Nakamura Carthamin contained sheet-shaped cosmetic
KR20030001218A (en) * 2002-02-16 2003-01-06 이광현 Serotonin compounds extracted from Carthamus tinctorius and compositions containing the same
JP2003002819A (en) * 2001-06-22 2003-01-08 Naris Cosmetics Co Ltd Skin care composition
JP2020033314A (en) * 2018-08-31 2020-03-05 日本メナード化粧品株式会社 Skin external preparation and internal agent containing extract of safflower cultivated by application of light in a specific wavelength region

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240510A (en) * 2000-03-01 2001-09-04 Kenji Nakamura Carthamin contained sheet-shaped cosmetic
JP2003002819A (en) * 2001-06-22 2003-01-08 Naris Cosmetics Co Ltd Skin care composition
KR20030001218A (en) * 2002-02-16 2003-01-06 이광현 Serotonin compounds extracted from Carthamus tinctorius and compositions containing the same
JP2020033314A (en) * 2018-08-31 2020-03-05 日本メナード化粧品株式会社 Skin external preparation and internal agent containing extract of safflower cultivated by application of light in a specific wavelength region

Also Published As

Publication number Publication date
JP3206952B2 (en) 2001-09-10

Similar Documents

Publication Publication Date Title
AU738015B2 (en) Dermatological compositions
JPH08119825A (en) Hydroxytyrosol, application for skin external medicine or bathing agent
JP3193441B2 (en) Whitening cosmetics
JPH06128138A (en) Cosmetic
JP2000128765A (en) Skin cosmetic
KR101078888B1 (en) A cosmetic composition comprising tissue cultured Echinaceae adventitious roots and an preparing method thereof
JP3558349B2 (en) Whitening cosmetics
JP2002212021A (en) Cosmetic
JP3170040B2 (en) Whitening cosmetics
JPH0987188A (en) Skin preparation for external use and bathing agent
DE4032972C2 (en) Use of glycoproteins extracted from gram-negative bacteria in cosmetic or dermatological compositions
JP3235922B2 (en) Cosmetics
JP3998085B2 (en) Hyaluronic acid amount increase accelerator
DE102007024679B4 (en) Use of cosmetically active agents to protect FGF-2
JPH05229956A (en) Antioxidant
DE3809801A1 (en) COSMETIC LIGHT PROTECTION PREPARATES AND METHOD FOR THE PRODUCTION THEREOF
JPH06336422A (en) External agent for skin
JP3235919B2 (en) Cosmetics
JP3176983B2 (en) Whitening cosmetics
WO2007144723A2 (en) Use of plants of carpobrotus edulis as anti-itching and/or anti-inflammatory agents
JP3792745B2 (en) Tyrosinase inhibitor
JP2000143527A (en) Hyaluronic acid production promoter and skin preparation for external use containing the same
JPH08259443A (en) Dermal composition for external use
JPH06329526A (en) Hyaluronidase-inhibiting agent
JPH06100427A (en) Agent for preventing chapped skin

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250